Pancreatic Adenocarcinoma | Norton Healthcare

Indication: Pancreatic Adenocarcinoma

PANOVA 3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for frontline treatment of locally-advanced pancreatic adenocarcinoma

Locally Advanced

Sub-indication: Locally advanced Pancreatic Adenocarcinoma

Line of Therapy: 1st line

Device/Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: NovoCure

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.